BRIEF-Adial Pharma Receives Positive Response From FDA Meeting Regarding Vitro Bridging Strategy For AD04

Reuters
25 Feb
BRIEF-Adial Pharma Receives Positive Response From FDA Meeting Regarding Vitro Bridging <a href="https://laohu8.com/S/MSTR">Strategy</a> For AD04

Feb 25 (Reuters) - Adial Pharmaceuticals Inc ADIL.O:

  • ADIAL PHARMACEUTICALS RECEIVES POSITIVE RESPONSE FROM FDA MEETING REGARDING PROPOSED IN VITRO BRIDGING STRATEGY FOR AD04

  • ADIAL PHARMACEUTICALS- MOVES FORWARD WITH MANUFACTURING CLINICAL SUPPLIES FOR PHASE 3 PROGRAM IN 2025

Source text: ID:nGNX9ZpY9Q

Further company coverage: ADIL.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10